Shares of CEL-SCI Corporation (AMEX: CVM) jumped more than 24 percent in morning trading Monday after the company announced plans to move forward with two highly-anticipated drug trials.
In addition to recent FDA approval to go ahead with clinical trials of CEL-SCI’s novel LEAPS-H1N1 flu medication, the company has also raised the capital necessary to go forward with Phase III clinical trials of its flagship cancer treatment, Multikine, which analysts believe could become a standard ...

News of Buzz Stocks Forum